top of page
Executive Spotlights

Biopharmaceutical Leader Thomas Smart Takes Helm as CEO at Actym Therapeutics

Berkeley, CA, April 24, 2024 (PRNewswire) -- Actym Therapeutics announced the appointment of Thomas Smart as its new Chief Executive Officer. With a rich career background of 25 years in executive positions within the biopharmaceutical industry, along with board memberships, Mr. Smart brings a wealth of experience to steer Actym through pivotal moments. His track record of steering companies through transformative periods aligns seamlessly with Actym's imminent venture into clinical evaluation, particularly with its flagship candidate, ACTM-838, slated for later in the year.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page